Core Viewpoint - The company is facing short-term financial impacts due to tax payment obligations and project delays, while also managing idle fundraising through financial investments. Recent Events - The subsidiary Suqian Hospital is required to pay back taxes and penalties totaling 8.41 million yuan for the period from 2022 to 2024, which has been fully paid [2]. Company Project Progress - The completion date for the "Core Raw Materials and High-end Pharmaceutical Intermediates Common Production Platform Construction Project" has been postponed from March 2026 to March 2028, with only 2.57% of the investment progress achieved by September 2025. This delay may affect the long-term capacity layout [3]. Fund Movement - The subsidiary redeemed two fundraising investments, yielding a profit of 2.71 million yuan, and purchased new structured deposits totaling 156 million yuan with a term of 360 days. As of the announcement date, the balance of unexpired fundraising investments is 680 million yuan [4]. Recent Stock Performance - The stock price is reported at 7.99 yuan per share, with a daily increase of 2.04% and a net inflow of 949,400 yuan in principal funds. For the period from January to September 2025, the revenue was 2.38 billion yuan, and the net profit attributable to shareholders was 68.46 million yuan. The number of shareholders as of January 30 was 33,500, a decrease of 1.98% from the previous period [5]. Industry Policy and Environment - The pharmaceutical industry is expected to face increased concentration and deepened support policies for innovative drugs by 2026, which may drive the company's transformation [6].

Core Viewpoint - On February 23, a total of 34 listed companies had their restricted shares unlocked, with a total market value of approximately 19.007 billion yuan [1] Group 1: Restricted Share Unlocking Details - Luzhou Laojiao (000568) had 2.0425 million shares unlocked under equity incentive restrictions - AVIC Xi'an Aircraft Industry (000768) had 4.3606 million shares unlocked under equity incentive restrictions - Hubei Energy (000883) had 19.2779 million shares unlocked under equity incentive restrictions - Jining Pharmaceutical (000919) had 1.92 million shares unlocked under equity incentive restrictions - Guangji Pharmaceutical (000952) had 2.5209 million shares unlocked under equity incentive restrictions - China Software (600536) had 57,200 shares unlocked under equity incentive restrictions - Xinhua Medical (600587) had 1.7845 million shares unlocked under equity incentive restrictions - Baoxin Software (600845) had 10.2578 million shares unlocked under equity incentive restrictions - China Railway (601390) had 55.9338 million shares unlocked under equity incentive restrictions - China Communications Construction (601800) had 5.593 million shares unlocked under equity incentive restrictions - StarNet Ruijie (002396) had 2.8342 million shares unlocked under equity incentive restrictions - Lopuskin (002333) had 22.3212 million shares unlocked under A-share issuance to legal persons - Wanbangda (300055) had 33.6538 million shares unlocked under A-share issuance to legal persons - Hangyang Co., Ltd. (002430) had 5.2049 million shares unlocked under equity incentive restrictions - Taijia Co., Ltd. (002843) had 949,600 shares unlocked under equity incentive restrictions - Nanda Optoelectronics (300346) had 130,000 shares unlocked under equity incentive restrictions - Anhui Natural Gas (603689) had 2.5064 million shares unlocked under equity incentive restrictions - Zhongyan Dadi (003001) had 97,200 shares unlocked under equity incentive restrictions - Yuanxiang New Materials (301300) had 30.2983 million shares unlocked with extended lock-up period - Yidao Information (001314) had 88.6187 million shares unlocked under pre-issuance restrictions - Tongda Electric (603390) had 579,500 shares unlocked under equity incentive restrictions - Yangzhou Jinqiao (603307) had 50 million shares unlocked under pre-issuance restrictions - Aili Home (603221) had 2.29 million shares unlocked under equity incentive restrictions - Zhili Fang (301312) had 333,900 shares unlocked under equity incentive restrictions - Kuntai Co., Ltd. (001260) had 83.25 million shares unlocked under pre-issuance restrictions - Entropy Technology (301330) had 92.5223 million shares unlocked with extended lock-up period - Yatong Precision (603190) had 596,100 shares unlocked under pre-issuance restrictions - Sanwang Communication (688618) had 87,400 shares unlocked - Longxun Co., Ltd. (688486) had 30.6312 million shares unlocked - Dize Pharmaceutical (688192) had 991,100 shares unlocked - Haohan Depth (688292) had 57.5177 million shares unlocked - Haizheng Biomaterials (688203) had 78.5601 million shares unlocked - Diaomicro (688381) had 55.9536 million shares unlocked - Zhongrun Optics (688307) had 29.8507 million shares unlocked [1]

Group 1 - The company’s subsidiary, Nanjing Gulou Hospital Group Suqian Hospital, is required to pay back taxes and penalties totaling 8.4115 million yuan for the period from 2022 to 2024 as per the tax authority's decision [1] - The total amount of back taxes and penalties has been fully paid as of the date of the announcement, and this matter does not involve any administrative penalties [1] - The payment of these taxes and penalties will be recorded in the company's profit and loss for the year 2025, and the final impact on the net profit attributable to shareholders will be determined based on the audited financial statements for that year [1] Group 2 - The company assures that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1] - The tax payment does not constitute a prior accounting error and will not require retrospective adjustments to previous financial data [1] - The company states that this tax matter will not have a significant impact on its production and operations [1]

Core Viewpoint - Jinling Pharmaceutical (000919.SZ) announced that its subsidiary, Nanjing Gulou Hospital Group Suqian Hospital Co., Ltd. (referred to as "Suqian Hospital"), received a tax processing decision from the Suqian Tax Bureau, requiring the hospital to pay back taxes and penalties totaling 8.4115 million yuan for the period from 2022 to 2024 [1] Group 1 - Suqian Hospital has fully paid the required back taxes and penalties as of the announcement date [1] - The tax payment does not involve any administrative penalties [1]

Core Viewpoint - Jinling Pharmaceutical (000919.SZ) announced that its subsidiary, Nanjing Gulou Hospital Group Suqian Hospital Co., Ltd., received a tax handling decision from the Suqian Tax Bureau, requiring the payment of tax and late fees totaling 8.4115 million yuan for the period from 2022 to 2024 [1] Group 1 - The tax and late fees have been fully paid as of the date of the announcement [1] - The tax issue does not involve any administrative penalties [1]

Core Viewpoint - Jinling Pharmaceutical (000919) announced that its subsidiary, Nanjing Gulou Hospital Group Suqian Hospital Co., Ltd., has received a tax handling decision from the Suqian Tax Bureau, requiring the payment of tax and late fees totaling 8.4115 million yuan for the period from 2022 to 2024 [1] Group 1 - The tax and late fees have been fully paid as of the date of the announcement [1] - The tax payment does not involve any administrative penalties [1]

Core Viewpoint - Jinling Pharmaceutical (000919.SZ) announced that its subsidiary, Nanjing Gulou Hospital Group Suqian Hospital Co., Ltd. (referred to as "Suqian Hospital"), received a tax processing decision from the Suqian Tax Bureau, requiring the hospital to pay back taxes and late fees totaling 8.4115 million yuan for the period from 2022 to 2024 [1] Group 1 - Suqian Hospital has fully paid the required back taxes and late fees as of the date of the announcement [1] - The tax payment does not involve any administrative penalties [1]

证券代码： 000919 证券简称：金陵药业 公告编号：2026-007 金陵药业股份有限公司 关于子公司补缴税款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、基本情况 金陵药业股份有限公司（以下简称"公司"）控股子公司南京鼓 楼医院集团宿迁医院有限公司（以下简称"宿迁医院"）近日收到国 家税务总局宿迁市税务局稽查局的税务处理决定书，根据税务机关的 要求，宿迁医院需补缴 2022 年至 2024 年期间的税款及滞纳金 841.15 万元。截止本公告日，上述税款及滞纳金已经全部缴纳，本次不涉及 行政处罚。 二、对公司的影响 根据《企业会计准则第 28 号—会计政策、会计估计变更和差错 更正》相关规定，上述补缴税款事项不属于前期会计差错，不涉及前 期财务数据追溯调整。上述缴纳的税款及滞纳金计入公司 2025 年当 期损益，对公司 2025 年度归属于上市公司股东的净利润的具体影响 最终以 2025 年度经审计的财务报表为准。本事项不会对公司生产经 营产生重大影响，敬请广大投资者注意投资风险。 特此公告。 金陵药业股份有限公司董事会 2026 年 2 ...

Group 1 - The core point of the article is that Jinling Pharmaceutical reported its shareholder count as of February 10, 2026, which stands at 34,654 households [2]

Meeting Overview - The first extraordinary general meeting of shareholders for 2026 was held on February 5, 2026, at 14:30, combining both on-site and online voting methods [2][3] - The meeting was presided over by the chairman, Mr. Chen Sheng, and complied with relevant laws and regulations [3][10] Attendance - A total of 205 shareholders attended the meeting, representing 37,147,263 shares, which is 5.9730% of the total voting shares [4][5] - Among them, 2 shareholders attended in person, representing 14,800 shares (0.0024%), while 203 shareholders participated via online voting, representing 37,132,463 shares (5.9706%) [4][5] Voting Results - The proposal regarding the expected daily related transactions for 2026 was approved, with 34,922,902 shares in favor (94.0120%), 2,059,361 shares against (5.5438%), and 165,000 shares abstaining (0.4442%) [9] - The related shareholder, Nanjing New Industry Investment Group Co., Ltd., abstained from voting on this proposal, holding 259,390,380 shares [8] Legal Opinion - The legal opinion provided by Jiangsu Taihe Law Firm confirmed that the meeting's procedures and voting results were in compliance with applicable laws and regulations [10]